ELMED Life Sciences, a science-led company focused on probiotic and biological solutions across animal health, aquaculture, agriculture and human health has successfully raised $2.7 Million (₹25 crore) in Series A funding from AgriSURE Fund, an agri-focused investment fund managed by NABVENTURES, the venture capital arm of NABARD. This investment will support the company’s next phase of growth, focused on expanding its manufacturing, strengthening R&D, and scaling distribution across key markets.
Founded by Pruthivin Reddy Madduri & co-founded by Nikhil Konkathi, ELMED Life Sciences is working towards advancing biological solutions that improve productivity, immunity, and sustainability across farm ecosystems. The company operates across four key segments: animal health, agriculture, aquaculture, and human health, offering probiotic-based solutions tailored to the needs of poultry, dairy, livestock, shrimp, fish farming, and soil/plant health.
The investment comes at a time when the global and Indian agriculture ecosystem is witnessing a significant shift towards biological and microbiome-based solutions, driven by increasing regulatory restrictions on antibiotic usage, rising export standards for residue-free produce, and growing awareness around sustainable farming practices. In India, the probiotic segment across animal health, aquaculture, and agriculture is growing rapidly, with adoption accelerating across poultry, dairy, and aquaculture sectors.
With the new funding, ELMED Life Sciences aims to expand its manufacturing capabilities in Hyderabad while strengthening its research and development in microbiome-based solutions. The company is also focused on deepening its distribution network across Tier 2 and Tier 3 markets in India and building a stronger presence in international markets driven by rising demand for sustainable, antibiotic-free solutions.
“We founded ELMED Life Sciences with one conviction that nature’s own biological intelligence, when harnessed through rigorous science, can transform the health and productivity of animals, humans, aquatic systems, and soil. The support of the AgriSURE Fund is a strategic partnership with an institution that understands this market from the ground up. With this funding, we are ready to take ELMED to its next chapter: deeper into the heart of Indian agriculture, and broader into global markets that increasingly demand clean, biological, and residue-free solutions. The opportunity ahead of us is immense, and we are only getting started.” Pruthivin Reddy Madduri, Founder & Managing Director, ELMED Life Sciences
Speaking about the investment, Ashish Choudhary, Investment Manager, AgriSURE Fund, NABVENTURES, said, “Indian agriculture is steadily moving towards more sustainable and residue-free practices, creating a strong need for reliable biological solutions. Through the AgriSURE Fund, we focus on backing businesses that can drive this shift at scale. ELMED has demonstrated both scientific strength and on-ground adoption across key agri segments, and this investment will support its next phase of growth in manufacturing and market expansion.”
“ELMED operates in a rapidly emerging segment within the probiotic and biological solutions space, with strong growth potential. The company’s positioning and scalability make it a compelling opportunity. We are pleased to have supported this funding.” Sumeet Seraf, Founder & CEO, Equity360
ELMED Life
ELMED Life Sciences currently operates across India from its headquarters based out of Hyderabad, India, and serves multiple notable MNC’s through aB2B approach across industries.
The company is also expanding its global footprint and currently exports to more than 18 countries, with plans to further strengthen its presence acrossEurope, Asia & South American (LATAM) countries going forward. ELMED is the first company in India to research and develop probiotics specifically for agriculture.
Over the next few years, ELMED aims to significantly scale its operations, focusing on expansion across domestic and international markets while continuing to invest in science-backed innovation in biological solutions, focusing on ONE HEALTH.
